These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9829060)

  • 1. Somatuline LA: a new treatment for acromegaly.
    Bouloux PM
    Hosp Med; 1998 Aug; 59(8):642-5. PubMed ID: 9829060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of acromegaly with a new slow release somatostatin analog, lanreotide].
    Boucekkine C; Catus F; Blumberg-Tick J; Pholséna M; Chanson P; Schaison G
    Ann Endocrinol (Paris); 1994; 55(6):261-9. PubMed ID: 7864583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.
    Strasburger CJ; Karavitaki N; Störmann S; Trainer PJ; Kreitschmann-Andermahr I; Droste M; Korbonits M; Feldmann B; Zopf K; Sanderson VF; Schwicker D; Gelbaum D; Haviv A; Bidlingmaier M; Biermasz NR
    Eur J Endocrinol; 2016 Mar; 174(3):355-62. PubMed ID: 26744896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly.
    Heron I; Thomas F; Dero M; Gancel A; Ruiz JM; Schatz B; Kuhn JM
    J Clin Endocrinol Metab; 1993 Mar; 76(3):721-7. PubMed ID: 8095269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incomplete analgesic effect of lanreotide in acromegaly.
    Maffei P; Martini C; Sicolo N
    Headache; 1997 May; 37(5):299-300. PubMed ID: 9195771
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
    Biermasz NR; Roelfsema F; Pereira AM; Romijn JA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):223-34. PubMed ID: 19527094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depot somatostatin analogs--a new first line therapy for acromegaly.
    Robbins RJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):15-7. PubMed ID: 8989224
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lanreotide++: a new therapeutic option in acromegaly].
    Díez JJ
    Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatuline Autogel: an extended release lanreotide formulation.
    Lightman S
    Hosp Med; 2002 Mar; 63(3):162-5. PubMed ID: 11933820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
    Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
    Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin].
    Sánchez R; Boix E; del Pino Navarro M; Picó A
    Med Clin (Barc); 1999 Jul; 113(5):198. PubMed ID: 10480146
    [No Abstract]   [Full Text] [Related]  

  • 14. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
    Drange MR; Melmed S
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the formulation and delivery of somatostatin analogs for acromegaly.
    Fattah S; Brayden DJ
    Ther Deliv; 2017 Oct; 8(10):867-878. PubMed ID: 28944744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome?].
    Bouché O; Salmon-Ettersperger L; Frémond L; Thiéfin G; Zeitoun P
    Gastroenterol Clin Biol; 1997; 21(1):84-5. PubMed ID: 9091398
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
    Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
    J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
    [No Abstract]   [Full Text] [Related]  

  • 20. Large fat and skin necroses after deep subcutaneous injections of a slow-release somatostatin analogue in a woman with acromegaly.
    Burman P; Besjakov J; Svensjö T
    Growth Horm IGF Res; 2010 Dec; 20(6):438-40. PubMed ID: 21071248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.